Sintilimab
达伯舒(Tyvyt)
A Chinese-developed PD-1 immunotherapy — the first PD-1 to enter China's national insurance, at a fraction of imported prices.
At a glance
China price
Verified pricing is not currently available.
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
Source(s)
- https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500227/YPSN202500227.pdf
Official / government source
NRDL (national insurance)
In NRDL since 2019 — the low-cost reimbursed PD-1 option.
Regulatory status
NMPA approved; NRDL 2025(2025/2026 - 202520251231)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
Hodgkin lymphoma, NSCLC, liver, gastric and esophageal cancers.
(mijian360.com)826verified
Sources & verification
- https://www.nhsa.gov.cn/attach/Ypsn2025/YPSN202500227/YPSN202500227.pdf — Official / government source
Reader discussion
Public comments about Sintilimab. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.